LCTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.1M
-38.0%
1.7M
-73.9%
6.6M
+79.5%
3.7M
+33.1%
2.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
1.1M
-38.0%
1.7M
-73.9%
6.6M
+79.5%
3.7M
+33.1%
2.8M
Operating Expenses
10.0M
+7.2%
9.3M
-29.2%
13.2M
+76.2%
7.5M
-66.9%
22.5M
R&D
4.8M
+12.8%
4.2M
-48.6%
8.2M
+151.8%
3.3M
+5.3%
3.1M
SG&A
5.2M
+2.6%
5.1M
+4.8%
4.9M
+15.8%
4.2M
-8.1%
4.6M
Operating Income
-8923000
-17.5%
-7593000
-16.0%
-6548000
-73.0%
-3786000
+80.9%
-19780000
EBITDA
-8736000
-18.0%
-7405000
-16.4%
-6362000
-76.3%
-3608000
+24.3%
-4769000
Net Income
1.5M
+132.2%
-4789000
-636.9%
892.0K
+103.0%
-29752000
+2.0%
-30364000
EPS (Basic)
$0.01
+150.0%
$-0.02
$0.00
+100.0%
$-0.13
+0.0%
$-0.13
EPS (Diluted)
$-0.03
+0.0%
$-0.03
$0.00
+100.0%
$-0.13
+0.0%
$-0.13
Shares (Diluted)
261.5M
+0.1%
261.2M
+10.1%
237.2M
+3.6%
228.9M
+0.2%
228.4M
Lineage Cell Therapeutics (LCTX) โ€” Financials